Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis launched its urology business in early 2015, which includes a patented formulation to address patients suffering from interstitial cystitis.
San Diego, US
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has office in San Diego
San Diego, US

Imprimis Pharmaceuticals Metrics

Imprimis Pharmaceuticals Summary

Market capitalization

$31.7 m

Closing share price

Imprimis Pharmaceuticals's current market capitalization is $31.7 m.

Imprimis Pharmaceuticals Financials

Imprimis Pharmaceuticals's revenue is $1.7 m in FY, 2014 which is a 82.9% decrease from the previous period.
FY, 2014FY, 2015


$1.7 m$9.7 m

Revenue growth, %


Net Income

($10.1 m)($15.9 m)

Imprimis Pharmaceuticals Market Value History

Imprimis Pharmaceuticals Online Presence

Imprimis Pharmaceuticals News

Imprimis Pharmaceuticals Company Life

You may also be interested in